Let’s Align Your Program with Clinically Interpretable Data
Our translational science team will work with you to align mechanism, model selection, exposure logic, and decision objectives before screening begins.
Services
3DTwin® Dynamic and Translational Drug Response Profiling
Patient-derived 3D microtumour screening to capture longitudinal drug response dynamics for translational oncology decisions.
Translating in vitro tumor response into patient-relevant outcome insight.
Functional Outcome Profiling for Translational Decisions
The 3DTwin® service delivers standardized, longitudinal functional profiling of drug response in 3D cancer models, ranging from established cell lines to patient-derived tumors.
Rather than relying on static IC50 or endpoint viability measurements, 3DTwin captures growth response kinetics, treatment adaptation, and regrowth behavior under clinically anchored exposure conditions.
This enables comparative and clinically interpretable evaluation of compounds and combinations across diverse cancer models, supporting confident translational and early development decisions.
Longitudinal growth-response kinetics instead of static endpoints
Comparative profiling across diverse 3D cancer models
Standardized 384-well microtumor production and automated quantification
Clinically anchored benchmarking using standard-of-care reference drugs
Clinically anchored benchmarking using standard-of-care reference drugs
How 3DTwin® Projects Are Structured for Translational Confidence
Every 3DTwin® project follows a structure, phase-gated framework designed to align biological relevance, exposure logic, and decision objectives before large-scale screening begins.
Set-Up & Mechanistic Alignment
- Understand drug mechanism of action (MOA) and clinical development intent
- Select or engineer fit-for-purpose 3D cancer models
- Define clinically anchored dosing strategy and treatment schedule
Why this matters:
Ensures biological model, exposure conditions, and decision objectives are aligned before data generation begins.
Model Qualification
- Biological and functional quality control
- Validation against reference and standard-of-care compounds
- Pre-defined go / no-go decision before cohort expansion
Why this matters:
Establishes model robustness and translational interpretability before scaling.
Cohort Screening
- Screening across patient-relevant cohort sizes
- Longitudinal growth-response profiling
- Outcome-based response stratification
- Identification of sensitive and resistant subgroups
Why this matters:
Growth kinetics, response classification, and comparative benchmarks
Integrated Molecular & Phenotypic Characterization
Because 3DTwin® longitudinal efficacy profiling is non-destructive, microtumors remain viable throughout the assay. This enables the integration of additional molecular and phenotypic analyses on the same biological system without disrupting core functional readouts.
Depending on study objectives, transcriptomic profiling, protein expression analysis, or other downstream assays can be incorporated to contextualize observed response dynamics. These layers enhance mechanistic interpretation while preserving the integrity of the primary functional outcome assessment.
Engagement & Deployment Models
3DTwin® combines distributed screening with centralized analytics, supporting flexible deployment aligned with translational goals.
Projects feed into a growing cross-model dataset, enabling benchmarking against standard-of-care and approved therapies.
Full Service (Centralized Execution)
PreComb performs model setup, qualification, screening, and analysis at its Zurich-based 3DTwin™ Profiler APEX facility.
Best suited for:
- Early-stage programs
- Exploratory translational projects
- Customers without in-house screening infrastructure
Hybrid Deployment
Customers provide tissue or biological material, while screening and analysis are performed using standardized 3DTwin™ infrastructure and workflows.
Ensures:
- Biological alignment with customer programs
- Maintained platform standardization
- Centralized data interpretation
Distributed / Self-Service Deployment
The 3DTwin™ Profiler FLEX system, manufactured with Tecan hardware and operated using PreComb test kits, enables decentralized screening at partner sites.
All data is processed through PreComb’s centralized analytics environment to maintain cross-site comparability and translational consistency.
All deployment models utilize proprietary PreComb reference drug plates and standardized assay kits. This ensures controlled exposure conditions, benchmarking against standard-of-care therapies, and consistent functional interpretation across projects and institutions.
Where 3DTwin®
adds the Most Value
3DTwin® is particularly valuable when translational decisions require clinically interpretable functional data rather than static endpoint measurements.
3DTwin® can support a broad range of oncology drug development questions. It is particularly advantageous when:
Early translational prioritization when compound selection must be informed by durable functional response, not just potency metrics
Indication and cohort exploration across diverse cancer types or biological backgrounds
Combination strategy evaluation where treatment adaptation and regrowth dynamics influence outcome
Assessment of response durability and resistance patterns in a controlled, longitudinal in vitro system